The mRNA vaccine, a swift warhead against a moving infectious disease target
Introduction The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases. Initially met with skepticism, mRNA vaccines have proven effective and safe, reducing vaccine hesitancy amid the evolving COVID-19...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2320327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141411042263040 |
|---|---|
| author | Sheema Mir Mohammad Mir |
| author_facet | Sheema Mir Mohammad Mir |
| author_sort | Sheema Mir |
| collection | DOAJ |
| description | Introduction The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases. Initially met with skepticism, mRNA vaccines have proven effective and safe, reducing vaccine hesitancy amid the evolving COVID-19 pandemic. The COVID-19 pandemic has demonstrated that the time required to modify mRNA vaccines to counter new mutant strains is significantly shorter than the time it takes for pathogens to mutate and generate new variants that can thrive in vaccinated populations. This highlights the notion that mRNA vaccine technology appears to be outpacing viruses in the ongoing evolutionary race.Areas covered This review article offers valuable insights into several crucial aspects of mRNA vaccine development and deployment, including the fundamentals of mRNA vaccine design and synthesis, the utilization of delivery systems, considerations regarding vaccine safety, the longevity of the immune response, strategies for modifying the original mRNA vaccine to address emerging mutant strains, as well as addressing vaccine hesitancy and potential approaches to mitigate reluctance.Expert opinion Challenges such as stability, storage, manufacturing complexities, production capacity, allergic reactions, long-term effects, accessibility, and misinformation must be addressed. Despite these hurdles, mRNA vaccine technology holds promise for revolutionizing future vaccination strategies. |
| format | Article |
| id | doaj-art-b04e5746a24f400d8fc1337eb19d5b54 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-b04e5746a24f400d8fc1337eb19d5b542024-12-04T09:49:47ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123133634810.1080/14760584.2024.2320327The mRNA vaccine, a swift warhead against a moving infectious disease targetSheema Mir0Mohammad Mir1College of Veterinary Sciences, Western University of Health Sciences, Pomona, CA, USACollege of Veterinary Sciences, Western University of Health Sciences, Pomona, CA, USAIntroduction The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases. Initially met with skepticism, mRNA vaccines have proven effective and safe, reducing vaccine hesitancy amid the evolving COVID-19 pandemic. The COVID-19 pandemic has demonstrated that the time required to modify mRNA vaccines to counter new mutant strains is significantly shorter than the time it takes for pathogens to mutate and generate new variants that can thrive in vaccinated populations. This highlights the notion that mRNA vaccine technology appears to be outpacing viruses in the ongoing evolutionary race.Areas covered This review article offers valuable insights into several crucial aspects of mRNA vaccine development and deployment, including the fundamentals of mRNA vaccine design and synthesis, the utilization of delivery systems, considerations regarding vaccine safety, the longevity of the immune response, strategies for modifying the original mRNA vaccine to address emerging mutant strains, as well as addressing vaccine hesitancy and potential approaches to mitigate reluctance.Expert opinion Challenges such as stability, storage, manufacturing complexities, production capacity, allergic reactions, long-term effects, accessibility, and misinformation must be addressed. Despite these hurdles, mRNA vaccine technology holds promise for revolutionizing future vaccination strategies.https://www.tandfonline.com/doi/10.1080/14760584.2024.2320327SARS-CoV-2COVID19mRNA vaccinevirologyvaccine hesitancyin vitro mRNA synthesis |
| spellingShingle | Sheema Mir Mohammad Mir The mRNA vaccine, a swift warhead against a moving infectious disease target Expert Review of Vaccines SARS-CoV-2 COVID19 mRNA vaccine virology vaccine hesitancy in vitro mRNA synthesis |
| title | The mRNA vaccine, a swift warhead against a moving infectious disease target |
| title_full | The mRNA vaccine, a swift warhead against a moving infectious disease target |
| title_fullStr | The mRNA vaccine, a swift warhead against a moving infectious disease target |
| title_full_unstemmed | The mRNA vaccine, a swift warhead against a moving infectious disease target |
| title_short | The mRNA vaccine, a swift warhead against a moving infectious disease target |
| title_sort | mrna vaccine a swift warhead against a moving infectious disease target |
| topic | SARS-CoV-2 COVID19 mRNA vaccine virology vaccine hesitancy in vitro mRNA synthesis |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2320327 |
| work_keys_str_mv | AT sheemamir themrnavaccineaswiftwarheadagainstamovinginfectiousdiseasetarget AT mohammadmir themrnavaccineaswiftwarheadagainstamovinginfectiousdiseasetarget AT sheemamir mrnavaccineaswiftwarheadagainstamovinginfectiousdiseasetarget AT mohammadmir mrnavaccineaswiftwarheadagainstamovinginfectiousdiseasetarget |